Cystagon
Orphan DrugFDA Approved
Description
Cystagon is indicated for the treatment of nephropathic cystinosis. It reduces cystine accumulation in cells, leading to delayed progression of renal failure.
Indications & Therapeutic Use
Nephropathic cystinosis
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Cystagon
| Generic Name | Cystagon |
| Brands | 1 brand available |
| Active Ingredient | Cysteamine bitartrate |
| Drug Class | Nephropathic cystinosis |
| Manufacturer | Mylan |
| Dosage Forms | Capsule |
| Medical Code | A16AA04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes